Clindamycin Phosphate Topical Solution

Clindamycin Phosphate Topical Solution Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Clindamycin Phosphate Topical Solution is used to treat acne vulgaris. It is a topical (for the skin) antibiotic. This medication is available in generic form. Common side effects include burning, itching, dry skin, redness, oily skin, or peeling.

Apply a thin film of Clindamycin Phosphate Topical Solution or use a Clindamycin Phosphate Topical Solution pledget (pad) twice daily to affected area. More than one pledget may be used if needed. Discard any used pledgets and wash hands thoroughly after application. Clindamycin Phosphate Topical Solution may interact with other neuromuscular blocking agents. There may be other drugs that can interact with Clindamycin Phosphate Topical Solution. Tell your doctor all prescription and over-the-counter medications you are taking. Clindamycin Phosphate Topical Solution should be used during pregnancy only if prescribed. It is not known if the topical form of this medication passes in breast milk. Oral forms of clindamycin pass into breast milk. Consult your doctor before breast-feeding.

Our Clindamycin Phosphate Topical Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Clindamycin Phosphate Topical Solution FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

In 18 clinical studies of various formulations of topical Clindamycin Phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Number of Patients Reporting Events

Treatment Emergent
Adverse Event
Solution
n=553 (%)
Gel
n=148 (%)
Lotion
n=160 (%)
Burning 62 (11) 15 (10) 17 (11)
Itching 36 ( 7 ) 15 (10) 17 (11)
Burning/Itching 60 (11) # (-- ) # (-- )
Dryness 105 (19) 34 (23) 29 (18)
Erythema 86 (16) 10 ( 7 ) 22 (14)
Oiliness/Oily Skin 8 ( 1 ) 26 (18) 12*(10)
Peeling 61 (11) # (-- ) 11 ( 7 )
# not recorded
* of 126 subjects

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).

Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.

Read the entire FDA prescribing information for Clindamycin Phosphate Topical Solution (Clindamycin Phosphate Topical Solution) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.